Eman Z Kandeel1, Lobna Refaat1, Raafat Abdel-Fatah2, Mohamed Samra2, Ahmed Bayoumi3, Mona S Abdellateif4, Hend Abdel-Hady1, Mohamed Ali2, Medhat Khafagy5. 1. Clinical Pathology Department, National Cancer Institute, Cairo University, Giza, Egypt. 2. Medical Oncology Department, National Cancer Institute, Cairo University, Giza, Egypt. 3. Pediatric Oncology Department, National Cancer Institute, Cairo University, Giza, Egypt. 4. Cancer Biology Department, National Cancer Institute, Cairo University, Giza, Egypt. 5. Surgical Oncology Department, National Cancer Institute, Cairo University, Giza, Egypt.
Abstract
BACKGROUND: COVID-19 viral pandemic caused many mortalities in cancer patients especially those with hematological malignancies. The immunological response to COVID-19 infection is responsible for the outcome of cases whether mild, severe or critical. CASE PRESENTATION: Two cases presented with moderate COVID-19 viral infection, concomitant with acute myeloid leukemia and T acute lymphoblastic leukemia, respectively. Surprisingly, after the administration of COVID-19 supportive therapy, the cases showed disease remission after a follow-up period of 12 and 5 months, respectively. Additionally, the blast cells dropped to only 3% and 0% in the bone marrow aspirates of those two cases, respectively, after it was 30% in both cases at diagnosis. CONCLUSION: The immune response that emerged against COVID-19 infection could potentially produce anti-tumor immunity in some patients, or the virus may act as an oncolytic virus. However, further investigations are required to explain this phenomenon, which may help in finding a possible new targeted therapy for these cases.
BACKGROUND: COVID-19 viral pandemic caused many mortalities in cancer patients especially those with hematological malignancies. The immunological response to COVID-19 infection is responsible for the outcome of cases whether mild, severe or critical. CASE PRESENTATION: Two cases presented with moderate COVID-19 viral infection, concomitant with acute myeloid leukemia and T acute lymphoblastic leukemia, respectively. Surprisingly, after the administration of COVID-19 supportive therapy, the cases showed disease remission after a follow-up period of 12 and 5 months, respectively. Additionally, the blast cells dropped to only 3% and 0% in the bone marrow aspirates of those two cases, respectively, after it was 30% in both cases at diagnosis. CONCLUSION: The immune response that emerged against COVID-19 infection could potentially produce anti-tumor immunity in some patients, or the virus may act as an oncolytic virus. However, further investigations are required to explain this phenomenon, which may help in finding a possible new targeted therapy for these cases.
Entities:
Keywords:
ALL; AML; COVID-19; case report; remission
Authors: P O Vorobyev; F E Babaeva; A V Panova; J Shakiba; S K Kravchenko; A V Soboleva; A V Lipatova Journal: Mol Biol Date: 2022-10-05 Impact factor: 1.540